drugset / Trial / NCT00362648

Developing World Study for RotaTeq™ (V260-015)(COMPLETED)

NCT00362648

Phase 3 Completed 7504 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupDouble-blindPrevention

Summary

The purpose of the current study is to evaluate whether the vaccine is effective, well-tolerated and immunogenic among infants in developing countries.

Timeline

Start
2007-03
Primary completion
2009-03
Completion
2009-03

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Rotarix Vaccine 2 ml Oral

Indications